PHIO
Price
$2.04
Change
-$0.02 (-0.97%)
Updated
Sep 5 closing price
Capitalization
11.68M
RPRX
Price
$36.07
Change
-$0.83 (-2.25%)
Updated
Sep 5 closing price
Capitalization
15.59B
59 days until earnings call
Interact to see
Advertisement

PHIO vs RPRX

Header iconPHIO vs RPRX Comparison
Open Charts PHIO vs RPRXBanner chart's image
Phio Pharmaceuticals
Price$2.04
Change-$0.02 (-0.97%)
Volume$30.81K
Capitalization11.68M
Royalty Pharma
Price$36.07
Change-$0.83 (-2.25%)
Volume$9.23M
Capitalization15.59B
PHIO vs RPRX Comparison Chart in %
Loading...
PHIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RPRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
PHIO vs. RPRX commentary
Sep 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PHIO is a StrongBuy and RPRX is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 07, 2025
Stock price -- (PHIO: $2.04 vs. RPRX: $36.07)
Brand notoriety: PHIO and RPRX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: PHIO: 2% vs. RPRX: 289%
Market capitalization -- PHIO: $11.68M vs. RPRX: $15.59B
PHIO [@Biotechnology] is valued at $11.68M. RPRX’s [@Biotechnology] market capitalization is $15.59B. The market cap for tickers in the [@Biotechnology] industry ranges from $101.56B to $0. The average market capitalization across the [@Biotechnology] industry is $1.91B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PHIO’s FA Score shows that 0 FA rating(s) are green whileRPRX’s FA Score has 1 green FA rating(s).

  • PHIO’s FA Score: 0 green, 5 red.
  • RPRX’s FA Score: 1 green, 4 red.
According to our system of comparison, RPRX is a better buy in the long-term than PHIO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PHIO’s TA Score shows that 4 TA indicator(s) are bullish while RPRX’s TA Score has 2 bullish TA indicator(s).

  • PHIO’s TA Score: 4 bullish, 6 bearish.
  • RPRX’s TA Score: 2 bullish, 7 bearish.
According to our system of comparison, PHIO is a better buy in the short-term than RPRX.

Price Growth

PHIO (@Biotechnology) experienced а +3.55% price change this week, while RPRX (@Biotechnology) price change was +0.25% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.52%. For the same industry, the average monthly price growth was +14.52%, and the average quarterly price growth was +33.01%.

Reported Earning Dates

RPRX is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Biotechnology (+2.52% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RPRX($15.6B) has a higher market cap than PHIO($11.7M). RPRX has higher P/E ratio than PHIO: RPRX (15.75) vs PHIO (0.01). RPRX YTD gains are higher at: 44.156 vs. PHIO (13.333). PHIO has less debt than RPRX: PHIO (0) vs RPRX (8B).
PHIORPRXPHIO / RPRX
Capitalization11.7M15.6B0%
EBITDA-7.45MN/A-
Gain YTD13.33344.15630%
P/E Ratio0.0115.750%
Revenue0N/A-
Total Cash10.8MN/A-
Total Debt08B-
FUNDAMENTALS RATINGS
PHIO vs RPRX: Fundamental Ratings
PHIO
RPRX
OUTLOOK RATING
1..100
6266
VALUATION
overvalued / fair valued / undervalued
1..100
54
Fair valued
2
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9995
PRICE GROWTH RATING
1..100
6250
P/E GROWTH RATING
1..100
6376
SEASONALITY SCORE
1..100
4050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RPRX's Valuation (2) in the Pharmaceuticals Major industry is somewhat better than the same rating for PHIO (54) in the Biotechnology industry. This means that RPRX’s stock grew somewhat faster than PHIO’s over the last 12 months.

RPRX's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as PHIO (100) in the Biotechnology industry. This means that RPRX’s stock grew similarly to PHIO’s over the last 12 months.

RPRX's SMR Rating (95) in the Pharmaceuticals Major industry is in the same range as PHIO (99) in the Biotechnology industry. This means that RPRX’s stock grew similarly to PHIO’s over the last 12 months.

RPRX's Price Growth Rating (50) in the Pharmaceuticals Major industry is in the same range as PHIO (62) in the Biotechnology industry. This means that RPRX’s stock grew similarly to PHIO’s over the last 12 months.

PHIO's P/E Growth Rating (63) in the Biotechnology industry is in the same range as RPRX (76) in the Pharmaceuticals Major industry. This means that PHIO’s stock grew similarly to RPRX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
PHIORPRX
RSI
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
64%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
58%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
64%
MACD
ODDS (%)
Bullish Trend 2 days ago
88%
Bearish Trend 2 days ago
65%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
51%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
62%
Advances
ODDS (%)
Bullish Trend 16 days ago
83%
Bullish Trend 3 days ago
54%
Declines
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 12 days ago
61%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
51%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
70%
View a ticker or compare two or three
Interact to see
Advertisement
PHIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RPRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
XME83.932.36
+2.89%
SPDR® S&P Metals and Mining ETF
IDOG35.960.24
+0.66%
ALPS International Sector Div Dogs ETF
FFGX28.960.18
+0.62%
Fidelity Fundamental Global ex-U.S. ETF
JPXN84.340.51
+0.61%
iShares JPX-Nikkei 400 ETF
ELQD82.89N/A
N/A
iShares ESG Advanced Investment Grade

PHIO and

Correlation & Price change

A.I.dvisor indicates that over the last year, PHIO has been closely correlated with RIGL. These tickers have moved in lockstep 84% of the time. This A.I.-generated data suggests there is a high statistical probability that if PHIO jumps, then RIGL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PHIO
1D Price
Change %
PHIO100%
-0.97%
RIGL - PHIO
84%
Closely correlated
+3.02%
CLNN - PHIO
83%
Closely correlated
+1.34%
DARE - PHIO
81%
Closely correlated
+0.94%
IMRN - PHIO
71%
Closely correlated
-1.69%
TPST - PHIO
51%
Loosely correlated
+9.57%
More

RPRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, RPRX has been loosely correlated with SANA. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if RPRX jumps, then SANA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RPRX
1D Price
Change %
RPRX100%
-2.25%
SANA - RPRX
40%
Loosely correlated
-0.67%
PHIO - RPRX
39%
Loosely correlated
-0.97%
GLPG - RPRX
33%
Loosely correlated
+4.54%
SEER - RPRX
33%
Loosely correlated
+4.48%
XNCR - RPRX
31%
Poorly correlated
+2.15%
More